Mike Jeffries, the former CEO of Abercrombie & Fitch, has been diagnosed with dementia and late-onset Alzheimer’s disease, his legal team disclosed in court filings submitted Monday. The ...

ANF continues to report robust comparable sales growth in FQ3'24 while raising their FY2024 guidance for the third consecutive time - signaling its high growth cadence. The same has been observed ...

As the New Year approaches, the apparel industry is gearing up for fresh trends and evolving consumer preferences. From casual wear for hybrid work lifestyles to athletic gear for fitness-focused ...

This year, oil prices have averaged about $80 per barrel. “Fitch expects oil prices to decrease to USD70/bbl in 2025 from an average of USD80/bbl in 2024, due to moderating demand growth and ...

Fitch Ratings affirmed Mexican state-owned oil company Pemex's credit rating at B+, maintaining a stable outlook despite financial and operational issues that continue to limit the company's ...

Sandoz expects the settlement, which is subject to approval from a Pennsylvania federal court, to be finalized before the end of the year. Those involved in the settlement have the right to opt ...

Abercrombie & Fitch Co. operates as a specialty retailer of premium, high-quality casual apparel for men, women, and kids through a network of approximately 773 stores across North America ...

Ron Penney, a former deputy minister of justice for Newfoundland and Labrador and a fierce critic of the costly Muskrat Falls megaproject, says he'd like the newly announced memorandum of ...

That's where the innovators come in. Fierce Healthcare launched the Fierce 15 recognition in 2019, a time when digital health and telehealth startups were starting to gain ground. Our inaugural ...

Amanda Holden took to Instagram to defend her hosting debut of the Royal Variety Performance after fans had slammed her efforts. The Britain's Got Talent judge took to the stage with best pal Alan ...

In an emailed statement, a Roche spokesperson told Fierce Biotech that the company is discontinuing further development of Spark’s experimental hemophilia A gene therapy dirloctocogene ...

After its eye disease antibody flopped in an FDA-requested clinical trial in late November, Outlook Therapeutics is laying off 23% of staff. The move, which comes after an internal strategic ...